Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Treasury Shares (2017 - 2025)

Puma Biotechnology's Treasury Shares history spans 9 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 3.53% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 3.53%, while the annual FY2025 figure was $1.3 million, 3.53% up from the prior year.
  • Treasury Shares reached $1.3 million in Q4 2025 per PBYI's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.5 million in Q1 2021 to a low of $1.3 million in Q4 2024.
  • Average Treasury Shares over 5 years is $1.8 million, with a median of $1.8 million recorded in 2025.
  • Peak YoY movement for Treasury Shares: fell 24.53% in 2021, then grew 24.33% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $1.4 million in 2021, then grew by 7.32% to $1.5 million in 2022, then rose by 8.2% to $1.6 million in 2023, then decreased by 20.65% to $1.3 million in 2024, then increased by 3.53% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Treasury Shares are $1.3 million (Q4 2025), $1.4 million (Q3 2025), and $1.8 million (Q2 2025).